Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Mucopolysaccharidosis, MPS-IV-A

Known as: MPS IVA, Mucopolysaccharidosis Type IV A, Disease, Morquio A 
A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme galactosamine-6-sulfatase. It is characterized by skeletal… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Purpose:In this study, we aimed to describe the natural history of mucopolysaccharidosis I.Methods:Data from 1,046 patients who… Expand
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2014
2014
BACKGROUND Morquio syndrome A (mucopolysaccharidosis type IVA) is an autosomal recessive, life-limiting lysosomal storage disease… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BackgroundMucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder that results in the accumulation of… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Type I mucopolysaccharidosis (MPS I) is a lysosomal storage disorder caused by the deficiency of α-L-iduronidase, which results… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Mucopolysaccharidosis type I (MPS I) is a progressive and multisystemic disease, even in its attenuated Hurler-Scheie and Scheie… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Mucopolysaccharidoses (MPSs) are lysosomal storage diseases caused by a deficit in the enzymes needed for glycosaminoglycan (GAG… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A global, observational disease registry has been established to characterize the course of disease and track clinical outcomes… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Recombinant human alpha-L-iduronidase (Aldurazyme, laronidase) was approved as an enzyme replacement therapy for patients with… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Enzyme replacement therapy (ERT) has been developed for several lysosomal storage disorders, including mucopolysaccharidosis I… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Abstract. The lysosomal storage disorder, mucopolysaccharidosis type I (MPS I), is caused by a deficiency of the enzyme α-L… Expand
  • table 2
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?